Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: A systematic review.


Fesenfeld, M; Hutubessy, R; Jit, M; (2013) Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: A systematic review. Vaccine, 31 (37). pp. 3786-804. ISSN 0264-410X DOI: 10.1016/j.vaccine.2013.06.060

Full text not available from this repository. (Request a copy)

Abstract

The World Health Organization recommends establishing that human papillomavirus vaccination is cost-effective before vaccine introduction. We searched Pubmed, Embase and the Cochrane Library to 1 April 2012 for economic evaluations of human papillomavirus vaccination in low and middle income countries. We found 25 articles, but almost all low income countries and many middle income countries lacked country-specific studies. Methods, assumptions and consequently results varied widely, even for studies conducted for the same country. Despite the heterogeneity, most studies conclude that vaccination is likely to be cost-effective and possibly even cost saving, particularly in settings without organized cervical screening programmes. However, study uncertainty could be reduced by clarity about vaccine prices and vaccine delivery costs. The review supports extending vaccination to low income settings where vaccine prices are competitive, donor funding is available, cervical cancer burden is high and screening options are limited.

Item Type: Article
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology
PubMed ID: 23830973
Web of Science ID: 324444200007
URI: http://researchonline.lshtm.ac.uk/id/eprint/1236224

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
249Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item